S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:FNCH

Finch Therapeutics Group - FNCH Stock Forecast, Price & News

$0.35
-0.06 (-13.58%)
(As of 03/28/2023 05:23 PM ET)
Add
Compare
Today's Range
$0.32
▼
$0.38
50-Day Range
$0.36
▼
$0.55
52-Week Range
$0.30
▼
$5.45
Volume
567,473 shs
Average Volume
169,200 shs
Market Capitalization
$16.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Finch Therapeutics Group MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,757.1% Upside
$17.00 Price Target
Short Interest
Healthy
0.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Finch Therapeutics Group in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$1,755 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

182nd out of 1,002 stocks

Biological Products, Except Diagnostic Industry

30th out of 166 stocks

See Top Rated MarketRank™ Stocks Here

FNCH stock logo

About Finch Therapeutics Group (NASDAQ:FNCH) Stock

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Stock News Headlines

March 25, 2023 | msn.com
Looking Into Finch Therapeutics Group's Return On Capital Employed
March 25, 2023 | finance.yahoo.com
Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations
March 28, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 23, 2023 | finance.yahoo.com
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 22, 2023 | americanbankingnews.com
Finch Therapeutics Group (NASDAQ:FNCH) versus Atara Biotherapeutics (NASDAQ:ATRA) Head-To-Head Contrast
January 24, 2023 | finance.yahoo.com
Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months
January 24, 2023 | marketwatch.com
Finch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCH
January 24, 2023 | finance.yahoo.com
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
March 28, 2023 | Investing Daily (Ad)
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
November 11, 2022 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)
November 11, 2022 | finance.yahoo.com
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
November 9, 2022 | finance.yahoo.com
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
October 24, 2022 | finance.yahoo.com
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
October 1, 2022 | seekingalpha.com
FNCH Finch Therapeutics Group, Inc.
September 1, 2022 | finance.yahoo.com
After Takeda ends collaboration, microbiome startup Finch Therapeutics cuts 50 jobs
September 1, 2022 | markets.businessinsider.com
Finch Therapeutics To Reduce Workforce - Quick Facts
September 1, 2022 | finance.yahoo.com
Finch Therapeutics Provides Business Update
August 11, 2022 | finance.yahoo.com
Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results
August 10, 2022 | finance.yahoo.com
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
July 20, 2022 | nasdaq.com
As Finch Therapeutics Group, Inc.'s market cap (NASDAQ:FNCH) drops to US$103m, insiders might be questioning their decision to buy earlier this year
July 20, 2022 | finance.yahoo.com
As Finch Therapeutics Group, Inc. (NASDAQ:FNCH) drops to US$103m market cap, insiders might rethink their US$650k stock purchase earlier this year
June 2, 2022 | finance.yahoo.com
Finch Therapeutics to Participate in Upcoming June Investor Conferences
May 16, 2022 | finance.yahoo.com
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 9, 2022 | finance.yahoo.com
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
May 2, 2022 | nz.finance.yahoo.com
Finch Therapeutics Group, Inc. (FNCH)
April 29, 2022 | finance.yahoo.com
Why Finch Therapeutics Stock Is Skyrocketing Today
April 20, 2022 | finance.yahoo.com
Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs
See More Headlines
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Company Calendar

Last Earnings
11/10/2021
Today
3/28/2023
Next Earnings (Estimated)
5/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FNCH
CUSIP
N/A
CIK
1733257
Web
www.finchtherapeutics.com
Phone
617-229-6499
Fax
N/A
Employees
191
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+4,757.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.41)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,650,000.00
Net Margins
-13,315.45%
Pretax Margin
-13,315.45%
Return on Equity
-68.64%
Return on Assets
-48.64%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
5.08
Quick Ratio
5.08

Sales & Book Value

Annual Sales
$860,000.00
Price / Sales
19.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.00 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
48,150,000
Free Float
26,672,000
Market Cap
$16.85 million
Optionable
Not Optionable
Beta
-0.01

Key Executives

  • Dr. Mark Burnham Smith Ph.D. (Age 35)
    CEO & Director
    Comp: $698.66k
  • Mr. Marc B. Blaustein C.F.A. (Age 59)
    CFA, MPP, COO, Principal Financial & Accounting Officer
    Comp: $378.21k
  • Mr. Joseph D. Vittiglio Esq. (Age 50)
    J.D., Chief Bus. & Legal Officer and Corp. Sec.
    Comp: $526.08k
  • Mr. Bryan Gillis M.B.A.
    Chief Technology Officer
  • Mr. James S. Sigler (Age 61)
    Exec. VP of CMC
  • Dr. Howard Franklin M.B.A.
    M.D., Chief Medical Officer
  • Dr. Alka Batycky Ph.D.
    Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FNCH Stock - Frequently Asked Questions

Should I buy or sell Finch Therapeutics Group stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Finch Therapeutics Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FNCH shares.
View FNCH analyst ratings or view top-rated stocks.

What is Finch Therapeutics Group's stock price forecast for 2023?

2 equities research analysts have issued twelve-month price objectives for Finch Therapeutics Group's shares. Their FNCH share price forecasts range from $17.00 to $17.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 4,757.1% from the stock's current price.
View analysts price targets for FNCH or view top-rated stocks among Wall Street analysts.

How have FNCH shares performed in 2023?

Finch Therapeutics Group's stock was trading at $0.48 at the start of the year. Since then, FNCH shares have decreased by 27.1% and is now trading at $0.35.
View the best growth stocks for 2023 here.

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a decline in short interest in March. As of March 15th, there was short interest totaling 95,000 shares, a decline of 51.7% from the February 28th total of 196,500 shares. Based on an average daily trading volume, of 180,600 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.6% of the company's stock are sold short.
View Finch Therapeutics Group's Short Interest.

When is Finch Therapeutics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our FNCH earnings forecast.

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) released its earnings results on Wednesday, November, 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.21. The firm earned $11.34 million during the quarter. Finch Therapeutics Group had a negative net margin of 13,315.45% and a negative trailing twelve-month return on equity of 68.64%.

When did Finch Therapeutics Group IPO?

(FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

What is Finch Therapeutics Group's stock symbol?

Finch Therapeutics Group trades on the NASDAQ under the ticker symbol "FNCH."

Who are Finch Therapeutics Group's major shareholders?

Finch Therapeutics Group's stock is owned by many different institutional and retail investors. Top institutional investors include MSD Partners L.P. (0.32%), Renaissance Technologies LLC (0.26%), Millennium Management LLC (0.15%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jeffery A Smisek, Marc Blaustein and Nicholas Haft.
View institutional ownership trends.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Finch Therapeutics Group's stock price today?

One share of FNCH stock can currently be purchased for approximately $0.35.

How much money does Finch Therapeutics Group make?

Finch Therapeutics Group (NASDAQ:FNCH) has a market capitalization of $16.85 million and generates $860,000.00 in revenue each year. The company earns $-114,650,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How many employees does Finch Therapeutics Group have?

The company employs 191 workers across the globe.

How can I contact Finch Therapeutics Group?

The official website for the company is www.finchtherapeutics.com. The company can be reached via phone at 617-229-6499 or via email at ir@finchtherapeutics.com.

This page (NASDAQ:FNCH) was last updated on 3/28/2023 by MarketBeat.com Staff